Galectin-3 is also thought to compromise the activity of cytotoxic CD8+ T cells during some autoimmune diseases as well as in the tumor microenvironment (Fortuna-Costa et al., 2014, Kouo et al., 2015, Nangia-Makker et al., 2008). Here, LGALS3 is linked to neoplasm.